Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Company also plans to continue development of AZD1446 for Alzheimer’s disease
Subscribe to our email newsletter
AstraZeneca is likely to conduct further development of AZD3480, by initiating phase IIb studies in attention deficit/hyperactivity disorder (ADHD). It has agreed to make a $10 million milestone payment to Targacept.
AstraZeneca also plans to continue development of AZD1446 (TC-6683) for Alzheimer’s disease. AZD1446 is currently in phase-I, and was discovered in the ongoing AstraZeneca-Targacept research collaboration.
The company has prioritized the development of AZD1446 over further development of AZD3480. AZD3480 and AZD1446 are selective alpha4beta2 NNR agonists.
AstraZeneca is engaged in the research, development, manufacturing and marketing of prescription medicines. The company is focused on gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.